Cargando…
E670G PCSK9 polymorphism in HeFH & CAD with diabetes: is the bridge to personalized therapy within reach?
OBJECTIVE: To assess the distribution of PCSK9 E670G genetic polymorphism and PCSK9 levels in patients with Coronary Artery Disease (CAD) and Heterozygous Familial Hypercholesterolemia (HeFH), based on the presence of type 2 Diabetes Mellitus (T2DM). METHODS: The study included 201 patients with chr...
Autores principales: | Alieva, Rano, Shek, Aleksandr, Abdullaev, Alisher, Fozilov, Khurshid, Khoshimov, Shovkat, Abdullaeva, Guzal, Zakirova, Dariya, Kurbanova, Rano, Kan, Lilia, Kim, Andrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646404/ https://www.ncbi.nlm.nih.gov/pubmed/38028979 http://dx.doi.org/10.3389/fcdhc.2023.1277288 |
Ejemplares similares
-
Personalized rosuvastatin therapy in problem patients with partial statin intolerance
por: Shek, Aleksandr B., et al.
Publicado: (2018) -
Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial
por: Raal, Frederick, et al.
Publicado: (2023) -
Simvastatin intolerance genetic determinants: some features in ethnic Uzbek patients with coronary artery disease
por: Shek, Aleksandr B., et al.
Publicado: (2017) -
Can metformin stabilize PCSK9 level in stable coronary artery disease patients treated with statins?
por: Shek, Aleksandr B., et al.
Publicado: (2019) -
Culturally diverse families of young children with ASD in Sweden: Parental explanatory models
por: Zakirova-Engstrand, Rano, et al.
Publicado: (2020)